Terms: = Endocrine gland cancer AND PSA AND Treatment
46 results:
1. Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
Yong CM; Yehgambaram PAP; Lee SWH
PLoS One; 2024; 19(2):e0298130. PubMed ID: 38300930
[TBL] [Abstract] [Full Text] [Related]
2. Sol-gel synthesis and cytotoxicity evaluation of selenium-doped cerium oxide nanoparticles for biomedical applications.
Javid H; Amiri H; Hashemi SF; Reihani A; Esparham A; Hashemy SI
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3437-3447. PubMed ID: 37962586
[TBL] [Abstract] [Full Text] [Related]
3. Prostate cancer Metastasis to the Pituitary gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time.
Ataikiru O; Abdelsalam M; Avileli M; Hynes T
Curr Oncol; 2021 Oct; 28(6):4291-4297. PubMed ID: 34898537
[TBL] [Abstract] [Full Text] [Related]
4. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
Moya-Alarcón C; González-Domínguez A; Ivanova-Markova Y; Gimeno-Ballester V; Barretina-Ginesta MP; Pérez-Fidalgo JA; Redondo A
Gynecol Oncol; 2022 Feb; 164(2):406-414. PubMed ID: 34844775
[TBL] [Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Kharat AA; Nelson R; Au T; Biskupiak J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
[No Abstract] [Full Text] [Related]
6. Prognostic impact of splenic vessel involvement and tumor size in distal pancreatectomy for adenocarcinoma: a retrospective multicentric cohort study.
Gantois D; Guilbaud T; Scemama U; Girard E; Picaud O; Lefevre M; Elgani M; Hamidou Z; Moutardier V; Balandraud P; Chirica M; Barbier L; Fuks D; Birnbaum DJ
Langenbecks Arch Surg; 2022 Feb; 407(1):153-165. PubMed ID: 34373941
[TBL] [Abstract] [Full Text] [Related]
7. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
Tan DS; Chan JJ; Hettle R; Ghosh W; Viswambaram A; Yu CC
J Gynecol Oncol; 2021 Mar; 32(2):e27. PubMed ID: 33559410
[TBL] [Abstract] [Full Text] [Related]
8. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
Harrison RF; Cantor SB; Sun CC; Villanueva M; Westin SN; Fleming ND; Toumazis I; Sood AK; Lu KH; Meyer LA
Gynecol Oncol; 2021 Apr; 161(1):56-62. PubMed ID: 33536126
[TBL] [Abstract] [Full Text] [Related]
9. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
Muston D; Hettle R; Monberg M; McLaurin KK; Gao W; Swallow E; Zhang S; Kalemaj I; Signorovitch J; Moore K
Gynecol Oncol; 2020 Nov; 159(2):491-497. PubMed ID: 32951894
[TBL] [Abstract] [Full Text] [Related]
10. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract] [Full Text] [Related]
11. Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.
Lv L; Jiang Y; Yin S; Hu Y; Chen C; Ma W; Jiang S; Zhou P
Endocrine; 2019 Nov; 66(2):310-318. PubMed ID: 31368083
[TBL] [Abstract] [Full Text] [Related]
12. In Situ Detection and Quantification of AR-V7, AR-FL, psa, and
El-Heliebi A; Hille C; Laxman N; Svedlund J; Haudum C; Ercan E; Kroneis T; Chen S; Smolle M; Rossmann C; Krzywkowski T; Ahlford A; Darai E; von Amsberg G; Alsdorf W; König F; Löhr M; de Kruijff I; Riethdorf S; Gorges TM; Pantel K; Bauernhofer T; Nilsson M; Sedlmayr P
Clin Chem; 2018 Mar; 64(3):536-546. PubMed ID: 29301749
[TBL] [Abstract] [Full Text] [Related]
13. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
Tran AQ; Erim DO; Sullivan SA; Cole AL; Barber EL; Kim KH; Gehrig PA; Wheeler SB
Gynecol Oncol; 2018 Feb; 148(2):329-335. PubMed ID: 29273308
[TBL] [Abstract] [Full Text] [Related]
14. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
[TBL] [Abstract] [Full Text] [Related]
15. Prostate cancer: endogenous chemical castration.
McCoy OO; Prasad MM; Singer N
BMJ Case Rep; 2016 Apr; 2016():. PubMed ID: 27126094
[TBL] [Abstract] [Full Text] [Related]
16. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.
Manchanda R; Legood R; Pearce L; Menon U
Gynecol Oncol; 2015 Dec; 139(3):487-94. PubMed ID: 26436478
[TBL] [Abstract] [Full Text] [Related]
17. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
Gharaibeh M; McBride A; Bootman JL; Abraham I
Br J Cancer; 2015 Apr; 112(8):1301-5. PubMed ID: 25791875
[TBL] [Abstract] [Full Text] [Related]
18. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract] [Full Text] [Related]
19. Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer.
Bian J; Li B; Kou XJ; Wang XN; Sun XX; Ming L
Asian Pac J Cancer Prev; 2014; 15(19):8409-11. PubMed ID: 25339038
[TBL] [Abstract] [Full Text] [Related]
20. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Fust K; Li X; Maschio M; Barron R; Weinstein MC; Parthan A; Walli-Attaei M; Chandler DB; Lyman GH
Gynecol Oncol; 2014 Jun; 133(3):446-53. PubMed ID: 24657302
[TBL] [Abstract] [Full Text] [Related]
[Next]
